bulk rna-seq data Search Results


simulated ovarian cell line bulk rna-seq data  (Genentech inc)
90
Genentech inc simulated ovarian cell line bulk rna-seq data
Simulated Ovarian Cell Line Bulk Rna Seq Data, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bulk+rna-seq+data/pmc11345431-337-35-21?v=Genentech+inc
Average 90 stars, based on 1 article reviews
simulated ovarian cell line bulk rna-seq data - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
bulk rna seq data  (Institut Curie)
86
Institut Curie bulk rna seq data
Bulk Rna Seq Data, supplied by Institut Curie, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bulk+rna-seq+data/pm42120423-542-43-49?v=Institut+Curie
Average 86 stars, based on 1 article reviews
bulk rna seq data - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
murine immune cell reference data  (Celldex Inc)
86
Celldex Inc murine immune cell reference data
a , b MC38 tumor-bearing male mice were treated i.p. with CTR, 40 μg anti-mouse CTLA4 antibody (mCTLA-4), or equimolar mouse ProCTLA-4 (mProCTLA-4) ( n = 5/group) on day 11 after tumor inoculation. 2 days later, Treg cells from the tumor, spleen, and dLN were analyzed by flow cytometry. The representative plot ( a ) and the frequency of Treg cells ( b ) from different treatment groups were shown. c – g Tumor-infiltrating CD45 + <t>immune</t> cells isolated from MC38 tumor-bearing male mice with different treatment (CTR, mCTLA-4, mProCTLA-4) were analyzed by scRNA-seq. c UMAP visualization of merged total CD45 + cells from three treatment groups. d Bar plot depicting the <t>cell</t> percentages of each cell type as a proportion of total cells. Feature plot illustrating gene expression of ICOS ( e ) and CTLA-4 ( f ) in Foxp3 + Treg cells. g Bar plot depicting the cell percentages of ICOS high Treg cells within total CD3 + T cells. h – j MC38 tumor-bearing male mice were treated i.p. with CTR, 10 μg mCTLA4, or equimolar mProCTLA4 on day 11 after tumor inoculation. 2 days after the treatment, the total Treg cells and ICOS high Treg cells ( h ) from tumors were analyzed by flow cytometry. The frequency and absolute number of total Treg cells ( i , j ) and ICOS high Treg cells ( k , l ) was quantified. m Female Rag1 -/- mice ( n = 5/group) were i.v. transferred with Tregs. 3 days post-transfer, the mice were challenged s.c. with MC38-OVA. Activated OT-Ι T cells were transferred 4 days later. 5 days after OT-Ι transfer, mice were treated with 100 μg mProCTLA-4 every three days for three times, and the tumor curve was monitored. <t>Data</t> in panels ( b , i – m ) representative of two independent experiments. Statistical analysis was performed using ordinary one-way ANOVA with multiple comparisons test ( b, i – l ), or two-way ANOVA with Tukey’s multiple comparisons test ( m ).
Murine Immune Cell Reference Data, supplied by Celldex Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bulk+rna-seq+data/pmc12514261-344-9-16?v=Celldex+Inc
Average 86 stars, based on 1 article reviews
murine immune cell reference data - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
bulk rna seq data analysis alithea genomics performed organoid lysis  (Alithea Genomics)
86
Alithea Genomics bulk rna seq data analysis alithea genomics performed organoid lysis
a , b MC38 tumor-bearing male mice were treated i.p. with CTR, 40 μg anti-mouse CTLA4 antibody (mCTLA-4), or equimolar mouse ProCTLA-4 (mProCTLA-4) ( n = 5/group) on day 11 after tumor inoculation. 2 days later, Treg cells from the tumor, spleen, and dLN were analyzed by flow cytometry. The representative plot ( a ) and the frequency of Treg cells ( b ) from different treatment groups were shown. c – g Tumor-infiltrating CD45 + <t>immune</t> cells isolated from MC38 tumor-bearing male mice with different treatment (CTR, mCTLA-4, mProCTLA-4) were analyzed by scRNA-seq. c UMAP visualization of merged total CD45 + cells from three treatment groups. d Bar plot depicting the <t>cell</t> percentages of each cell type as a proportion of total cells. Feature plot illustrating gene expression of ICOS ( e ) and CTLA-4 ( f ) in Foxp3 + Treg cells. g Bar plot depicting the cell percentages of ICOS high Treg cells within total CD3 + T cells. h – j MC38 tumor-bearing male mice were treated i.p. with CTR, 10 μg mCTLA4, or equimolar mProCTLA4 on day 11 after tumor inoculation. 2 days after the treatment, the total Treg cells and ICOS high Treg cells ( h ) from tumors were analyzed by flow cytometry. The frequency and absolute number of total Treg cells ( i , j ) and ICOS high Treg cells ( k , l ) was quantified. m Female Rag1 -/- mice ( n = 5/group) were i.v. transferred with Tregs. 3 days post-transfer, the mice were challenged s.c. with MC38-OVA. Activated OT-Ι T cells were transferred 4 days later. 5 days after OT-Ι transfer, mice were treated with 100 μg mProCTLA-4 every three days for three times, and the tumor curve was monitored. <t>Data</t> in panels ( b , i – m ) representative of two independent experiments. Statistical analysis was performed using ordinary one-way ANOVA with multiple comparisons test ( b, i – l ), or two-way ANOVA with Tukey’s multiple comparisons test ( m ).
Bulk Rna Seq Data Analysis Alithea Genomics Performed Organoid Lysis, supplied by Alithea Genomics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bulk+rna-seq+data/10__1016_slash_j__cpblue__2026__100015-312-0-4?v=Alithea+Genomics
Average 86 stars, based on 1 article reviews
bulk rna seq data analysis alithea genomics performed organoid lysis - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

Image Search Results


a , b MC38 tumor-bearing male mice were treated i.p. with CTR, 40 μg anti-mouse CTLA4 antibody (mCTLA-4), or equimolar mouse ProCTLA-4 (mProCTLA-4) ( n = 5/group) on day 11 after tumor inoculation. 2 days later, Treg cells from the tumor, spleen, and dLN were analyzed by flow cytometry. The representative plot ( a ) and the frequency of Treg cells ( b ) from different treatment groups were shown. c – g Tumor-infiltrating CD45 + immune cells isolated from MC38 tumor-bearing male mice with different treatment (CTR, mCTLA-4, mProCTLA-4) were analyzed by scRNA-seq. c UMAP visualization of merged total CD45 + cells from three treatment groups. d Bar plot depicting the cell percentages of each cell type as a proportion of total cells. Feature plot illustrating gene expression of ICOS ( e ) and CTLA-4 ( f ) in Foxp3 + Treg cells. g Bar plot depicting the cell percentages of ICOS high Treg cells within total CD3 + T cells. h – j MC38 tumor-bearing male mice were treated i.p. with CTR, 10 μg mCTLA4, or equimolar mProCTLA4 on day 11 after tumor inoculation. 2 days after the treatment, the total Treg cells and ICOS high Treg cells ( h ) from tumors were analyzed by flow cytometry. The frequency and absolute number of total Treg cells ( i , j ) and ICOS high Treg cells ( k , l ) was quantified. m Female Rag1 -/- mice ( n = 5/group) were i.v. transferred with Tregs. 3 days post-transfer, the mice were challenged s.c. with MC38-OVA. Activated OT-Ι T cells were transferred 4 days later. 5 days after OT-Ι transfer, mice were treated with 100 μg mProCTLA-4 every three days for three times, and the tumor curve was monitored. Data in panels ( b , i – m ) representative of two independent experiments. Statistical analysis was performed using ordinary one-way ANOVA with multiple comparisons test ( b, i – l ), or two-way ANOVA with Tukey’s multiple comparisons test ( m ).

Journal: Nature Communications

Article Title: A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice

doi: 10.1038/s41467-025-64081-y

Figure Lengend Snippet: a , b MC38 tumor-bearing male mice were treated i.p. with CTR, 40 μg anti-mouse CTLA4 antibody (mCTLA-4), or equimolar mouse ProCTLA-4 (mProCTLA-4) ( n = 5/group) on day 11 after tumor inoculation. 2 days later, Treg cells from the tumor, spleen, and dLN were analyzed by flow cytometry. The representative plot ( a ) and the frequency of Treg cells ( b ) from different treatment groups were shown. c – g Tumor-infiltrating CD45 + immune cells isolated from MC38 tumor-bearing male mice with different treatment (CTR, mCTLA-4, mProCTLA-4) were analyzed by scRNA-seq. c UMAP visualization of merged total CD45 + cells from three treatment groups. d Bar plot depicting the cell percentages of each cell type as a proportion of total cells. Feature plot illustrating gene expression of ICOS ( e ) and CTLA-4 ( f ) in Foxp3 + Treg cells. g Bar plot depicting the cell percentages of ICOS high Treg cells within total CD3 + T cells. h – j MC38 tumor-bearing male mice were treated i.p. with CTR, 10 μg mCTLA4, or equimolar mProCTLA4 on day 11 after tumor inoculation. 2 days after the treatment, the total Treg cells and ICOS high Treg cells ( h ) from tumors were analyzed by flow cytometry. The frequency and absolute number of total Treg cells ( i , j ) and ICOS high Treg cells ( k , l ) was quantified. m Female Rag1 -/- mice ( n = 5/group) were i.v. transferred with Tregs. 3 days post-transfer, the mice were challenged s.c. with MC38-OVA. Activated OT-Ι T cells were transferred 4 days later. 5 days after OT-Ι transfer, mice were treated with 100 μg mProCTLA-4 every three days for three times, and the tumor curve was monitored. Data in panels ( b , i – m ) representative of two independent experiments. Statistical analysis was performed using ordinary one-way ANOVA with multiple comparisons test ( b, i – l ), or two-way ANOVA with Tukey’s multiple comparisons test ( m ).

Article Snippet: Cell types were predicted using SingleR (v.2.4.1) based on murine immune cell reference data (ImmGenData) from Celldex (v.1.12.0).

Techniques: Flow Cytometry, Isolation, Gene Expression